All In Biotech

Drug Trial Radar · NCT05369975

Efficacy and Safety in Imlifidase Desensitized Kidney Tx Patients, Including Two Non-Comparative Reference Cohorts

A Controlled, Open-label PA Efficacy and Safety Study in Imlifidase Desensitised Kidney Tx Patients With Positive XM Against a Deceased Donor Prior to Imlifidase Treatment, Including Non-comparative Registry and Concurrent Reference Cohorts

Last checked: Nov 19, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

113

Actual

Start

Apr 19, 2022

Primary completion

Apr 21, 2026

Study completion Apr 21, 2026

Sponsor

Lead sponsor
Hansa Biopharma ABIndustry
Sponsor type
Industry
First posted
May 11, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An open-label post authorization efficacy and safety study evaluating graft failure-free survival at 1-year in highly sensitized end-stage renal disease (ESRD) patients with positive crossmatch (XM) against a deceased donor prior to desensitized with imlifidase and subsequent kidney transplantation. Two non-comparative reference cohorts are included to assess the impact of differences in post-transplantation management and outcome in less sensitized patients.

Conditions

  • Kidney Transplantation in Highly Sensitized Patients

Interventions

  • ImlifidaseDrug

    Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.

  • Normal Transplantation RoutineOther

    Transplantation and pre- and post-transplantation therapies in accordance with the clinic's normal transplantation routine.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Graft failure-free survival 1 year after transplantation following imlifidase treatmentTime frame: 12 months after transplantation

Locations

22 sites in 11 countries. Site status is shown where the registry gives one.

  • Medizinische Universitaet Wien

    Vienna, Austria

  • UZ Leuven - Campus Gasthuisberg

    Leuven, Belgium

  • Institut klinicke a experimentalni mediciny (IKEM)

    Prague, Czechia

  • Centre Hospitalier Universitaire (CHU) de Rouen - Hôpital de Bois-Guillaume

    Bois-Guillaume, France

  • CHU de Grenoble - Hôpital Michallon

    La Tronche, France

  • Hôpital Necker - Enfants Malades

    Paris, France

  • Charité - Universitätsmedizin Berlin

    Berlin, Germany

  • Klinikum rechts der Isar der Technische Universitaet Muenchen

    Munich, Germany

  • Azienda Ospedaliera di Padova

    Padova, Italy

  • Azienda Ospedaliero - Universitaria di Parma

    Parma, Italy

  • University Medical Center Groningen

    Groningen, Netherlands

  • Leiden University Medical Center

    Leiden, Netherlands

  • Erasmus University Medical Center

    Rotterdam, Netherlands

  • Department of Nephrology , Zaloška 7

    Ljubljana, Slovenia

  • Hospital Del Mar, Servicio de Nefrología

    Barcelona, Spain

  • Hospital Clínic de Barcelona, Unidad de Trasplante Renal

    Barcelona, Spain

  • Vall d'Hebron University Hospital (HUVH)

    Barcelona, Spain

  • Hospital 12 de Octubre

    Madrid, Spain

  • Karolinska University Hospital

    Huddinge, Sweden

  • Uppsala University Hospital

    Uppsala, Sweden

  • St. James University Hospital

    Leeds, United Kingdom

  • Leicester General Hospital

    Leicester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.